GLP-1 Drugs for Obese Heart Failure Patients: Comprehensive Meta-Analysis | Research

The takeaway

Systematic review and meta-analysis of RCTs and matched cohorts confirms GLP-1 receptor agonists show cardiovascular benefits in obese HFpEF patients.

RCTs + matched cohorts pooled
Most comprehensive evidence review of GLP-1 drugs in obese HFpEF to date

What the researchers found

Comprehensive meta-analysis of RCTs and propensity-matched cohorts demonstrates GLP-1 RA efficacy in obese HFpEF patients, with benefits including weight loss and anti-inflammatory effects.

Why it matters

Obesity-related HFpEF is the fastest-growing form of heart failure. GLP-1 drugs may uniquely address both the obesity driver and the cardiac consequences.

How the study worked

Systematic review and meta-analysis including both randomized controlled trials and propensity score-matched cohort studies of GLP-1 RAs in obese HFpEF patients.

What this study cannot tell us

Combining RCTs and observational studies introduces heterogeneity. Specific GLP-1 agents may differ in cardiac effects.

How to read the evidence

Systematic review combining RCTs and matched cohorts — comprehensive evidence synthesis with moderate-to-high quality.

When this study was published

Published in 2026; includes the latest trial and real-world data.

The bigger picture

GLP-1 drugs may become the treatment of choice for obesity-phenotype HFpEF, addressing the root cause (obesity) while providing direct cardiovascular benefit.

Questions still open

Should all obese HFpEF patients receive GLP-1 drugs?
Which GLP-1 agent is best for HFpEF specifically?

Common questions

Can GLP-1 drugs help with heart failure?

For obese patients with HFpEF specifically, this meta-analysis shows GLP-1 drugs provide meaningful benefits through weight loss, reduced inflammation, and potential direct cardiac effects.

Is obesity a cause of heart failure?

Yes — obesity-related HFpEF is the fastest-growing form of heart failure. Excess weight causes the heart to stiffen and fill poorly, and GLP-1 drugs can address this by reducing weight and inflammation.

Read the original research

Efficacy of GLP-1 receptor agonists in obese patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized trials and propensity score-matched cohorts.

Current problems in cardiology, 51(1), 103194

View on PubMed ↗Publisher’s paper ↗

Citation

Caldeira Gaelzer, Giulia; Armani Prata, Alonzo; Gustavo Rizzolli, Luís; Mendes Afonso, Luisalice; Lenci Marques, Gustavo. (2026). Efficacy of GLP-1 receptor agonists in obese patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized trials and propensity score-matched cohorts.. Current problems in cardiology, 51(1), 103194. https://doi.org/10.1016/j.cpcardiol.2025.103194